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Abstract 
Skeletal muscle atrophy is defined as a decrease in muscle mass and occurs when protein degradation 
exceeds protein synthesis. Potential triggers of muscle wasting are long-term immobilization, 
malnutrition, severe burns, aging as well as various serious and often chronic diseases, such as chronic 
heart failure, obstructive lung disease, renal failure, AIDS, sepsis, immune disorders, cancer and 
dystrophies. Interestingly, a cooperation between several pathophysiological factors, including 
inappropriately adapted anabolic (e.g. growth hormone, insulin-like growth factor 1) and catabolic 
proteins (e.g. tumor necrosis factor alpha, myostatin), may tip the balance towards muscle-specific 
protein degradation through activation of the proteasomal and autophagic systems or the apoptotic 
pathway. Based on the current literature, we present an overview of the molecular and cellular 
mechanisms that contribute to muscle wasting. We also focus on the multi-facetted therapeutic 
approach that is currently employed to prevent the development of muscle wasting and to counteract its 
progression. This approach includes adequate nutritional support, implementation of exercise training 
and possible pharmacological compounds.  
 
 
 
 
1. Introduction 
Skeletal muscle is the most abundant tissue in the body of vertebrates and is involved in many different 
important functions. For instance, skeletal muscle is the primary target of glucose uptake, can regenerate 
after injury, and is subjected to size remodelling. Overall, skeletal muscle mass represents a determinant 
of strength, endurance and physical performance. Reduced muscle bulk or muscle atrophy takes place 
when protein degradation exceeds protein synthesis, leading to a reduction of the cross-sectional area of 
myofibers and decreased muscle strength. Though muscle atrophy is a consequence of certain 
physiological processes, such as aging, it may also be a prominent feature present in several disparate 
diseases. In this latter case, a general loss of body mass, not exclusively limited to muscle, inherently 
implies an underlying, usually chronic and severe syndrome with impaired prognosis, known as cachexia. 
In both physiological and pathological conditions, the clinical implications of muscle wasting translate 
into poor quality of life, implying exercise intolerance and inability to manage daily activity. Since our 
knowledge on the mechanisms contributing to muscle wasting has remarkably increased in the past 20 
years, the aim of the present review is to provide a comprehensive overview of the different cues, 
mechanisms and degradative machineries involved in muscle atrophy. Furthermore, an update is given 
on current therapeutic approaches. 
 
2. Muscle atrophy 
Muscle atrophy is a physiological consequence of aging (i.e. age-related sarcopenia), defined as the 
presence of both low muscle mass and low muscle function (strength or performance) [1], but it may also 
result from prolonged periods of rest or a sedentary lifestyle. Moreover, muscle atrophy represents a 
clinical feature of cachexia, a multifactorial syndrome implying reduced life expectancy and 
accompanying many illnesses like chronic heart failure (CHF), chronic obstructive pulmonary disease 
(COPD), chronic kidney disease (CKD), cancer, HIV, sepsis, immune disorders and dystrophies [2].  
A reduced cross-sectional area of myofibers with subsequent impaired strength is the main characteristic 
of muscle atrophy [3], mirroring a consistent depletion of contractile proteins. Muscle atrophy is also 
frequently characterised by a switch of the fiber-type composition. For instance, while the loss of 
contractile proteins predominantly affects the type II fast fibers during aging or cancer cachexia [3], 
giving rise to a higher proportion of slow versus fast fibers [4], an increase in type IIX fiber proportions at 
the expense of either type I or type IIA muscle fibers has been observed in CHF [5-7], suggesting that 
different pathophysiological cues may differently affect the fiber-type muscular pattern. Besides the loss 
of muscle mass, inherent deficits in the “quality” of skeletal muscle have been demonstrated. For 
instance, in symptomatic CHF patients, quadriceps muscle strength is reduced compared to controls, 
even after correction for reduced circumferential area [8]. Equally important, however, are the 
prognostic implications of cachexia and muscle loss. Anker et al. [9] provided strong evidence that the 
identification of a heart failure patient as being cachectic significantly increased the risk of dying, even 
after correction for age, gender, disease severity and treatment allocation. 
Until recently, the lack of a clear definition for cachexia has hampered structured research as well as the 
development of treatment targets. Therefore, in order to allow timely clinical recognition, objective 
criteria to define cachexia have become mandatory. According to the last consensus criteria, the 
condition sine qua non to define cachexia is weight loss greater than 5%, or weight loss greater than 2% 
in individuals already showing depletion according to current body weight and height (body-mass index 
[BMI] <20) or skeletal muscle mass [10]. However, the assessment for classification and clinical 
management of cachectic patients should include additional domains such as anorexia or reduced food 
intake, catabolic drive, muscle mass and strength as well as functional and psychosocial impairment. 
Altogether, these observations clearly indicate that different, somewhat apparently unrelated 
mechanisms may synergistically cooperate to trigger the impairment of body’s performance through loss 
of bulk muscle, thereby inducing critical and often fatal health complications.  
 
3. Triggers of muscle atrophy 
A dysbalance of anabolic versus catabolic factors may alter nitrogen balance leading to consistent protein 
depletion and muscle atrophy (Fig. 1). During embryonic development as well as in post-natal life, 
different anabolic factors are required to ensure proper muscle growth. In this context, growth hormone 
(GH), androgens (testosterone), insulin and insulin-like growth factor-1 (IGF-1) play a prominent role, 
with the latter being central due to its unrivalled pleiotropic ability to regulate different muscular 
mechanisms such as cell proliferation [11] and differentiation [12], myofiber growth [13,14] and 
regeneration [13]. Accordingly, low levels of circulating IGF-1 have been associated with sarcopenia [15], 
CHF [16], cancer [17] and other clinical syndromes [18]. Keeping in mind that IGF-1 exerts pleiotropic 
effects by stimulating proliferation of resident satellite cells during regeneration as well as growth of pre-
existing myofibers, it is conceivable that its decline in circulating levels during aging or in consequence of 
disease may impinge on the muscle architecture. Unlikely, liver-specific IGF-1 knock-out mice exhibit 
normal growth rates [19,20], suggesting that muscle-produced IGF-1 may compensate for the lack of 
systemic (hepatic) IGF-1. In support of the pivotal role of IGF-1, it has been reported that muscle-specific 
transgenic overexpression of IGF-1 promotes muscle hypertrophy and increases physiological muscle 
strength [13,21], improves muscle regeneration [13,22], ameliorates the dystrophic phenotype of mdx 
mice [23,24], protects motor neurons in a mouse model of amyotrophic lateral sclerosis (ALS) [25] and 
also attenuates disease in a mouse model of spinal and bulbar muscular atrophy [26]. In this regard, the 
beneficial IGF-1 effects mostly rely on the activation of the PI3K/AKT pathway, which promotes protein 
synthesis and blunts protein degradation [27-29]. Since insulin activates the PI3K/AKT pathway, 
analogously to IGF-1, insulin resistance plays a consistent role in muscle atrophy of diabetic patients [30]. 
Indeed, transgenic mice with a dominant-negative IGF-1 receptor specifically targeted to the skeletal 
muscle developed insulin resistance, due to formation of hybrid receptors between the mutant and the 
endogenous IGF-I and insulin receptors, thus providing an excellent model to study the molecular 
mechanisms underlying the development of human type 2 diabetes [31]. While sarcopenia occurring 
during aging mainly relates to impaired anabolism, because of decreased anabolic factors or reduced 
anabolic response [32,33], different conditions leading to muscle wasting show an increase of certain 
catabolic factors, including tumor necrosis factor-alpha (TNFα) [34,35], transforming growth-factor beta 
-39] and glucocorticoids [40-43]. Several tumor bearing animal 
increased expression of other cachectic cytokines, such as interleukin-1 (IL-1) [45] and IL-6 [46,47]. 
Another master regulator of muscle 
when administered to an adult animal [49], as, analogously, glucocorticoids do [50]. Finally, it is worth 
mentioning that protein degradation in skeletal muscle is stimulated by excessive oxidative stress [51], as 
discussed in more detail below. 
 
4. Molecular pathways underlying muscle atrophy 
Unraveling the signaling network that contributes to muscle depletion is pivotal to develop therapeutic 
interventions (Fig. 1). Among the different pathways controlling muscle size [28,29,52,53], the PI3K/Akt 
pathway is central and is mainly recruited upon IGF-1/insulin stimuli to promote protein synthesis and to 
block degradation [54-56]. In the cytoplasm, Akt1 activates S6 kinase 1 (S6K1) via mammalian target of 
rapamycin (mTOR), which leads to increased protein synthesis [57]. Akt1 phosphorylates also FoxO 
transcription factors, specifically making FoxO3 unable to enter the nucleus and to drive transcription of 
certain ubiquitin ligases (e.g. muscle atrophy F-Box (MAFbx/atrogin-1) and muscle RING finger-1 
(MuRF1)) [56] or autophagy-related genes (e.g. LC3 and Bnip3) [58], which account for the protein 
breakdown mediated by the ubiquitin-proteasomal and autophagic/lysosomal pathways [59], 
respectively (vide infra). Thus, constitutive Akt1 activation produces rapid muscle hypertrophy in 
transgenic mice [60,61], whereas Akt1/Akt2 double-knockout mice exhibit severe skeletal muscle atrophy 
[62]. Moreover, S6K1(-/-) myotubes are atrophic and their hypertrophic response to IGF-1, nutrients and 
membrane-targeted Akt1 is blunted [63], definitely corroborating the importance of the IGF-1/Akt axis 
pathway on the muscle maintenance.  
In support of this evidence, muscle atrophy due to reduced Akt signaling is observed in different diseases 
or pathophysiological conditions, including ALS [64-66], CKD [67,68], diabetes [30], chronic hypoxia [69], 
statin-induced myopathy [70], sepsis [71,72], burn injury [73] and aging [74]. In particular, different 
molecules behave as pro- -related 
weak inducer of apoptosis [76], glucocorticoids [77,78], angiotensin [79] and cisplatin [80]. It is 
noteworthy that one of the most powerful inducers of muscle atrophy, namely myostatin, can elicit 
activation of Smad2/3 pathway and increased expression of MAFbx/MURF1 ubiquitin ligases followed by 
increased proteasomal activity [81,82], thus contributing to the breakdown of sarcomeric proteins. 
Moreover, it has been recently shown that most of the myostatin effects rely on its ability to reduce the 
Akt signaling [83,84], as myostatin can inhibit the IGF-1-induced myotube hypertrophy by lowering Akt 
signaling [85]. 
Overall, these findings suggest that Akt is a valuable target for improvement of muscle performance in 
different pro-atrophic conditions. Of note, sustaining the Akt pathway confers also several advantages to 
Duchenne’s Muscular Dystrophy (DMD) muscles, as first observed upon IGF-1 administration to mdx mice 
[24]. Other studies showed that the activation of Akt in DMD muscles promotes hypertrophy [86,87], 
prevents the force drop induced by eccentric contractions [88], upregulates the utrophin-glycoprotein 
complex, promotes sarcolemma stability [89], attenuates muscular degeneration, promotes myofiber 
regeneration, improves muscle function [90] and mediates the hypertrophic effects promoted by matrix 
metalloproteinase-9 [91,92].  
Another pathway playing a consistent role in muscle atrophy relies on the activity of transcription factor 
NF-κB [93,94], which is frequently activated by several cytokines through a cascade involving the 
phosphorylation and consequent degradation of NF-κB inhibitor Iκ-Bα [95]. NF-κB pathway was first 
implicated in a model of skeletal muscle disuse atrophy [96]. Interestingly, NF-κB is able to directly bind 
the MURF1 promoter, thus triggering a proteasome-dependent muscle wasting [97]. In addition, NF-κB 
activation is tightly linked to increased oxidative stress, which in turn controls the rate of protein 
degradation in skeletal muscle [51]. Indeed, NF-κB induces muscle wasting through an increase in the 
expression of iNOS, leading to increased nitric oxide (NO) [98-101], as confirmed by the increased levels 
of protein nitration in aged muscle [102-105]. Thus, elevated NO levels are implicated in age-induced 
skeletal muscle apoptosis [106], in cytokine-induced cachexia [98,99,107] and iNOS expression is 
elevated in COPD [108] and human cancer and AIDS patients suffering from cachexia [109]. In addition, 
nNOS is commonly dislocated in neuromuscular disorders [110], such as ALS [111], and mediates muscle 
atrophy via regulation of FoxO transcription factors in a model of unloading-induced muscle atrophy 
[112]. Thus, the NO pathway may represent an effective target for the therapy of both muscle sarcopenia 
and cachexia [113]. 
In physiological conditions, a variety of reactive oxygen species (ROS) are produced in the skeletal muscle 
to allow the adaptation of the muscle to several stimuli [114]. In contrast, prolonged muscle disuse 
causes increased radical production and subsequent injury in inactive muscle fibers, as seen upon 
experimental immobilization of skeletal muscles. However, this effect can be delayed by exogenous 
antioxidants [115-117]. When ROS levels exceed the healthy threshold, at least three different signaling 
systems are supposed to play a central role in mediating the pro-atrophic effects on inactive muscles, 
namely the cytosolic calcium-dependent calpains, the mitogen activated protein kinase (MAPK) system 
that includes Jnk, p38 and Erk1/2 kinases, and the NF-κB pathway indeed [51,118]. 
 
5. Cellular mechanisms of protein degradation during muscle atrophy 
The two major protein degradation pathways in eukaryotic cells are the UPS (ubiquitin-proteasome 
system) and the autophagy-lysosome pathway (Fig. 1). In normal physiological conditions, the UPS is 
responsible for the degradation of short-lived proteins, whereas autophagy regulates levels of long-lived 
proteins and organelles. However, a large body of evidence suggests that both pathways also play an 
important role in skeletal muscle wasting. 
 
5.1. The ubiquitin-proteasome system 
Muscle-specific ubiquitin ligases 
Ubiquitin is an abundant 8 kDa peptide found in all cell types. To date, free ubiquitin has no biological 
function, but exerts its effects by covalent attachment to other proteins [119]. The substrate protein can 
be mono-ubiquitinated or additional ubiquitin molecules can be added to produce a poly-ubiquitinated 
protein that is targeted for degradation by the proteasome [120], while the mono-ubiquitinated 
substrates are likely degraded in the lysosomes [121]. The ubiquitination of proteins is a multi-step 
reaction [122,123]. The first step comprises activation of ubiquitin by ubiquitin activating enzyme (E1), an 
ATP hydrolyzing protein that adenylates ubiquitin on its C-terminal glycine and then links the ubiquitin 
molecule on a cysteine residue at its catalytic site. Subsequently, E1 transfers the activated ubiquitin to 
the active site of a ubiquitin conjugating enzyme (E2). Finally, E2 binds to a ligase (E3) that recognizes the 
substrate and transfers ubiquitin to the target protein. In mammalian cells, there is only one ubiquitin 
activating enzyme. The ubiquitin conjugating enzyme family is composed of several members that 
specifically interact with a subset of ubiquitin ligases which in turn recognize specific substrates 
[124,125]. 
In 2001, two muscle-specific ubiquitin ligases involved in the ubiquitination process of skeletal muscle 
proteins have been characterized, namely MAFbx/atrogin-1 and MuRF1 [126,127]. MAFbx is member of a 
multi-protein SCF (Skp1, Cullin1 and F-box) complex, which needs to be assembled first in order to 
establish E3 activity [127]. MuRF1 contains an N-terminal RING domain, a MuRF family conserved region, 
a zinc-finger domain (B-box), leucine-rich coiled-coil domains and an acidic C-terminal tail [128]. Knock-
out mice for either MAFbx or MuRF1 are phenotypically normal. However, under atrophy conditions, loss 
of a muscle-specific ubiquitin ligase confers partial protection against muscle wasting [126]. The 
molecular characterization of these ubiquitin ligases has led to the discovery that MuRF1 binds to the 
myofibrillar protein titin [128,129] and more importantly to the myosin heavy chain (MyHC), the most 
abundant protein in the skeletal muscle [130]. Indeed, MyHC was shown to be degraded by the 
proteasome [131] and loss of MyHC was blocked by siRNA-mediated inhibition of MuRF1 [130]. 
Moreover, MuRF1 is able to ubiquitinate MyHC in vitro [130]. More recent work showed that other 
myofibrillar proteins including myosin light chain and myosin-binding protein C are specifically 
ubiquitinated by MuRF1 [132]. The relevance of MAFbx in the stimulation of myofibrillar protein 
degradation is less clear. Hitherto, the only confirmed substrates for MAFbx are MyoD [133] and eIF3f 
[134]. MyoD is a transcription factor mainly involved in the myogenic program and partially in protein 
synthesis induction [135], while eIF3f is a translation initiation factor [136]. The role of MAFbx in protein 
synthesis rather than degradation was then suggested by reports showing no correlation between the 
rates of protein breakdown and the MAFbx mRNA levels both in vivo [137,138] and in vitro [139]. 
Moreover, expression of MAFbx/Atrogin-1 and MuRF-1 undergoes different regulation [140,141]. 
Because muscle atrophy results from both increased protein degradation and/or reduced synthesis, the 
two E3 ligases contribute most likely in a distinct manner to the wasting process. These observations 
should be taken into account when the measurement of mRNA levels of such E3s is taken as an indicator 
of proteasome-dependent protein degradation.  
After characterization of MAFbx and MuRF1, another muscle–specific ubiquitin ligase termed TRIM32 
was discovered in 2005 [142]. This protein was a tripartite motif (TRIM) family member containing in its 
structure a RING-finger, a B-box, and a coiled-coil motif. TRIM32 was shown to associate with the thick 
myofibrillar filament, and is able to ubiquitinate actin and dysbindin [142], a protein involved in 
lysosomal-endosomal trafficking [143]. Mutations in the E3 ubiquitin ligase TRIM32 are involved in 
skeletal muscle disorders such as Limb-girdle muscular dystrophy type 2H (LGMD2H) and the 
multisystemic disorder, Bardet-Biedl syndrome type 11 [144]. Skeletal muscles from murine TRIM32 
knock-out mice (T32KO) reveal mild myopathic changes such as Z-line streaming and a dilated 
sarcotubular system with vacuoles, thereby replicating phenotypes of LGMD2H and sarcotubular 
myopathy [145]. Analysis of T32KO neural tissue shows a decreased concentration of neurofilaments and 
a reduction in myelinated motoraxon diameters, suggesting a shift toward a slower motor unit type, as 
observed in T32KO soleus muscle. These data suggest that muscular dystrophy due to TRIM32 mutations 
involves both neurogenic and myogenic characteristics [145]. Finally, in 2007 a novel muscle-specific F-
box protein (FBXO40) was found to be upregulated after denervation, though not after starvation [146]. 
FBXO40 was previously identified in LGMD patients that showed a dramatic decrease in comparison to 
healthy individuals [147]. Very recently, FBXO40 was found to induce IRS1 ubiquitination in skeletal 
muscle, thereby providing a negative feedback on the pro-hypertrophic IGF1R/IRS1/PI3K/Akt pathway 
[148], as demonstrated by the enhanced body and muscle size of mice null for FBXO40 during the growth 
phase associated with elevated IGF1 levels. Future studies will reveal new substrates and specific new 
roles for E3 ubiquitin ligases, while more investigations in humans are needed to validate their potential 
role as therapeutic targets for the prevention of muscle atrophy. 
 
Proteasome induction/activation in muscle atrophy 
Several physiological factors such as classical hormones, insulin, IGF-1 and TNFα can modulate the 
expression of enzymes controlling ubiquitination and proteasome-dependent protein degradation. For 
example, insulin reduction as a consequence of fasting or experimental diabetes leads to increased 
expression of ubiquitin [30,41], MAFbx [149], as well as UBR1, UBR2, UBR3 [150,151]. Similar effects can 
be found after glucocorticoid administration [40-43], even though most of the glucocorticoid-induced 
effects are reverted by IGF-1 [42,43,152]. Also pro-inflammatory cytokines such as TNFα are responsible 
for increased ubiquitin expression and accumulation of ubiquitinated proteins [35,153]. However, the 
first observations indicating a role for the ubiquitin system during atrophy came from cancer cachexia 
models, showing increased ubiquitin and proteasome subunits expression or protein ubiquitination in 
tumor bearing animals [154-158]. Later, as MAFbx and MURF1 were discovered, their levels were 
reported to be increased in AH-130 bearing rats [17], as well as in MAC16 [159] and Colon-26 bearing 
mice [74,160]. After the identification of proteasome activation in cancer cachexia, similar observations 
were reported in atrophying muscles following denervation or starvation [161]. These experimental 
procedures led to the discovery of the ubiquitin ligases MAFbx and MURF1[126,127]. Worth of note, the 
atrophy of skeletal muscle following denervation is dependent on the upregulation of specific histone 
deacetylases  (HDAC), namely HDAC4 and HDAC5, which repress Dach2, a negative regulator of 
myogenin, resulting in the activation of myogenin which in turn drives the increase of MAFbx/Atrogin-1 
and MuRF-1 expression , leading to proteolytic muscle wasting [162]. Also sepsis-induced muscle atrophy 
associates with increased expression and enzymatic activity of the proteasome [163]. Subsequently, the 
raise in the mRNA levels of the ubiquitin ligases was reported [164]. Hitherto, a report showing increased 
MAFbx or MURF1 increase exists for almost every experimental condition characterized by muscle 
wasting, even if evidence for increased proteasome degradation is lacking. These conditions include 
disuse [126], diabetes [127,149], CKD [149], glucocorticoid administration [55], rheumatoid arthritis 
[165], COPD [166], alcohol-myopathy [167], AIDS [168], aging [132] and spinal cord injury [169]. 
 
5.2 Autophagy 
Autophagy is an evolutionarily conserved subcellular process for bulk destruction of proteins and entire 
organelles [170]. The process is classically considered to be a pathway contributing to cellular 
homeostasis and adaptation to stress, and thus may act as a pro-survival mechanism. However, excessive 
stimulation of the autophagic machinery is deleterious and may lead to caspase-independent cell death 
[171]. Different autophagic pathways have been described, all sharing the import of cytoplasmic 
components into the lysosome. For the most prevalent form of autophagy (macroautophagy, further 
referred to as autophagy), double-membrane vacuoles known as autophagosomes will form, originating 
from a largely undefined structure known as the phagophore or isolation membrane [170]. The process 
proceeds in a step-wise fashion, with the elongation of the isolation membrane, maturation of the 
autophagosome followed by its fusion with a lysosome, thereby generating an autolysosome. During this 
final step, the incorporation of the outer autophagosomal membrane with the lysosomal membrane 
eventually allows the degradation of the remaining inner single-membrane and the cytoplasmic content 
of the autophagosome by lysosomal hydrolases. So far, more than 30 autophagy-related (Atg) genes have 
been identified that regulate autophagy induction and autophagosome formation [172]. 
Autophagy is constitutively active at basal levels in skeletal muscle, as shown by the accumulation of 
autophagosomes in human myopathies caused by genetic deficiency of lysosomal proteins (e.g. Pompe’s 
and Danon’s disease) [173,174], or by pharmacological inhibition of lysosomal function, as in chloroquine 
myopathy [175]. Muscle-specific deletion of the essential autophagy gene Atg7 results in profound 
muscle atrophy and an age-dependent decrease in muscle force [176,177], suggesting that basal 
autophagy plays a beneficial role in controlling muscle mass. Moreover, Atg7 null muscles show 
accumulation of abnormal mitochondria, sarcoplasmic reticulum distension, disorganization of 
sarcomere, and formation of aberrant concentric membranous structures [176,177], indicating that basal 
autophagy in muscle is responsible for the removal of dysfunctional organelles and required for 
maintaining myofiber integrity. Because of an abnormal sarcoplasmic reticulum, Atg7 null muscles also 
reveal activation of ER chaperones, such as BiP, and phosphorylation of eIF2a [176,177], suggesting 
induction of an unfolded protein response. This condition leads to inhibition of protein synthesis, which 
further contributes to muscle atrophy. 
Even though basal autophagy is constitutively active and sufficient to keep myofibers in a healthy state 
during normal physiological conditions, several studies demonstrate that autophagy is strongly induced in 
skeletal muscle following oxidative stress [65,178] or in response to severe catabolic conditions such as 
denervation [179] or fasting [177]. The classical pathway that regulates autophagy in mammalian cells 
acts through mammalian target of rapamycin (mTOR), a protein kinase that plays a key role as an 
intracellular nutrient sensor and regulator of protein synthesis, cell growth and metabolism [172]. 
Surprisingly, mTOR signaling is not the major factor that controls autophagy in adult muscles. Detailed 
biochemical studies have shown that rapamycin-mediated mTOR inhibition only barely (~10%) increases 
protein breakdown in differentiated myotubes [180]. Instead, the transcription factor FoxO3 was found 
to be necessary (and sufficient) to activate autophagy in myotubes. Indeed, FoxO3 controls the 
expression of many autophagy-related genes, including microtubule-associated protein-1 light chain 3 
(LC3) involved in cargo recruitment and biogenesis of autophagosomes as well as Bnip3 [58,59]. Because 
autophagosome formation is not induced in (fed) mice overexpressing GFP-LC3 [177], LC3 induction per 
se is not sufficient to trigger autophagy. Most likely, LC3 is continuously consumed when autophagy is 
activated. In this way,  upregulation of LC3 is required to replenish the LC3 protein pool and allows 
progression of autophagy. In contrast, upregulation of Bnip3 has a major role in mediating the effect of 
FoxO3 on the autophagic process, as shown by the fact that induction of autophagy is markedly 
decreased by Bnip3 knockdown [58]. Other autophagy-related genes that are induced by FoxO3 during 
muscle atrophy are the LC3 homologue Gabarapl1, Atg12l and the lysosomal proteinase cathepsin L 
[58,59]. The role of cathespin L upregulation is still unclear. Possibly, cathepsin L is involved in the 
degradation of muscle-specific proteins, as shown recently for the sialidase Neu2 [181], a protein 
involved in myoblast differentiation. Unfortunately, and quite similar to autophagy inhibition, excessive 
activation of autophagy aggravates muscle wasting by removing portions of cytoplasm, proteins and 
organelles [182]. Therefore, tight control of FoxO3-induced gene expression is needed to avoid 
unbalanced autophagy induction and muscle loss. 
 
6. Apoptosis and muscle atrophy 
Cells undergoing apoptosis are characterized by cytoplasmic and nuclear condensation, oligonucleosomal 
cleavage of the chromosomal DNA, violent blebbing of the plasma membrane, packaging of the cellular 
contents into membrane-enclosed vesicles (apoptotic bodies) and elimination of these vesicles by 
heterophagocytosis [183,184]. Changes in membrane fluidity and ionic charge, altered behaviour of sugar 
chains or lipids, and conformational changes in membrane proteins are also likely to occur [183,184]. The 
morphological features of apoptosis are mainly the result of a subset of proteolytic enzymes, called 
caspases. These proteases are activated by two principal pathways: an intrinsic and an extrinsic one. The 
intrinsic pathway begins within the cell and is triggered by stress stimuli such as DNA damage. Hallmark 
events include mitochondrial outer membrane permeabilization (MOMP) and the release of cytochrome 
C through the permeability transition pore complex. Once released, cytochrome C binds apoptotic 
protease-activating factor 1 (Apaf-1) to form a complex known as the apoptosome. This complex also 
recruits procaspase-9, promoting its self-activation. Active caspase-9 in turn cleaves downstream effector 
caspases such as caspase-3 and caspase-7, which rapidly degrade intracellular substrates. The extrinsic 
pathway overlaps with the intrinsic pathway, and is activated by ligand binding to specific death 
-related apoptosis-inducing ligand (TRAIL) that bind to the TNF-receptor, Fas or TRAIL receptor, 
respectively.  
There is overwhelming evidence that apoptosis increases in skeletal muscle during normal aging 
[185,186], and thus may contribute to sarcopenia [187] (Fig. 1). First, the mitochondrion-mediated 
(intrinsic) signalling pathway is activated in aged skeletal muscle. Indeed, the content of several Bcl-2 
family members (Bax and Bcl-2) is altered with age, expression of Apaf-1 is enhanced, and the presence 
of cleaved caspases increases. There is also evidence that caspase-independent mechanisms may 
contribute to apoptosis through elevated nuclear levels of endonuclease G in aged muscle as well as 
raised expression levels of apoptosis inducing factor (AIF). Secondly, receptor-mediated apoptotic 
signalling may be activated in aging muscle, as shown by increased activation of caspase-8, increased 
expression of FADD, and increased mitochondrial content of tBid. These events most likely occur in 
whether this may lead to apoptotic cell death as some studies have shown elevated cytosolic levels while 
others have seen increases in nuclear p53. 
Apart from aging, apoptosis might contribute to muscle atrophy in various other conditions including 
cancer cachexia [188], CHF [189], muscle denervation [190], dystrophies [191], sepsis [192], hindlimb 
unweighting [193], muscle disuse [194] and burn injury [195]. However, with regard to interpretation of 
apoptosis data in muscle, several critical issues should be mentioned. Since skeletal myocytes are 
multinucleated, apoptosis of a particular nucleus may not equate to apoptosis of the entire muscle fiber. 
It is not yet known how many nuclei must be lost before the entire fiber undergoes apoptosis or how this 
process is regulated in skeletal muscle. Therefore, it has been suggested that nuclear apoptosis in skeletal 
muscle does not necessarily translate into death of the myofiber [186]. On the other hand, the classical 
terminal deoxynucleotidyl transferase end-labeling (TUNEL) technique is frequently used to detect DNA 
fragmentation during apoptosis, even though this method lacks specificity as it may also detect single-
stranded DNA or RNA breaks. Accordingly, false positive TUNEL reactions can be observed in living 
muscle cells during active gene transcription [196]. Other difficulties in interpreting cell death data in 
atrophying muscle stem from the observation that caspase-3 is not only involved in apoptosis, but also in 
myofibrillar protein degradation [197]. As occurs for calpains, caspase-3 might be involved in the release 
of myofibrillar proteins targeted to proteasome degradation. Also of note, caspase-3 enzyme activity has 
been reported to be elevated in aging muscle [198], while others have found no change in activity [185]. 
This discrepancy cannot simply be explained by differences in muscle type, age or animal strain, although 
differential expression of some anti-apoptotic proteins such as XIAP may help to understand 
contradictory study results [186]. 
 7. Therapeutic inhibition of muscle atrophy 
It is beyond the scope of this paper to extensively discuss the multitude of therapeutic approaches that 
have been explored until now to counteract or prevent muscle atrophy and excellent reviews on this 
subject have been published [199,200] Given that muscle wasting is a complex systemic disorder, it is 
likely that multiple actions are required to prevent its development and progression. Ideally, a multi-
facetted approach involves adequate nutritional support, the implementation of exercise training to 
stimulate muscle hypertrophy and, hopefully one or more pharmacological compounds that specifically, 
or because of pleiotropic actions, antagonize “pro-atrophic” pathways (Table 1). 
 
7.1. Malnutrition and weight loss 
Patients who suffer from life-threatening diseases are characterized by anorexia. Nevertheless, even 
bypassing the obstacle of reduced appetite by introducing enteral nutrition, or – if inevitable - total 
parenteral nutrition, does not reverse the wasting process. Therefore, nutritional optimisation should be 
considered as a supportive measure in malnourished patients. Deficiencies in micronutrients, vitamins, 
amino acids and electrolyte abnormalities need correction. For instance, previous observations in yeast 
suggested that branched-chain amino acids (BCAAs), leucine, isoleucine, and valine, might be potential 
candidates in promoting survival [201]. BCAAs increase the activity of mTORC1 (mTORC1; mTOR in 
complex with raptor), a key regulator of protein synthesis and cell growth [202], thus favouring cell 
oxidative capacity [203] and PGC-1α-mediated mitochondrial gene expression [204]. In addition, long-
term dietary supplementation with a specific BCAA-enriched amino acid mixture reduced oxidative 
damage, both in cardiac and skeletal muscles of middle aged mice, increasing average lifespan [205]. As 
such, BCAAs have been reported to have anti-cachectic effects, presumably resulting from interference 
with the UPS [206]. Moreover, in vitro experiments indeed demonstrated suppressed expression of 
MaFbx/atrogin-1 mRNA in a C2C12 cell line [207]. Fish oil derived N-3 polyunsaturated fatty acids (PUFAs) 
may have anti-catabolic effects through anti-inflammatory actions [208,209]. Despite their long term 
application on empirical grounds, appetite stimulants such as anti-histaminic drugs, as well as orally 
active progestational agents (megestrol acetate and medroxyprogesterone acetate) are still evaluated in 
clinical trials and have been approved for certain indications. The associated tendency for fluid retention 
limits their use in patients with CHF.  
The orexigenic hormone ghrelin as a potential means to target cachexia has recently received 
considerable attention [210]. The effects of synthetic human ghrelin, as well as ghrelin receptor agonists, 
are being evaluated in several trials. Ghrelin, predominantly produced by the stomach, increases food 
intake through its actions on the hypothalamus [211]. In addition, serving as a growth-hormone 
secretagogue and mainly mediating its effects via IGF-1, ghrelin also has anabolic effects. Both GH and 
insulin resistance have indeed been demonstrated in cachexia-related conditions. 
Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic 
pathway and may play a role in cancer cachexia, as well as in CHF patients [212]. Chronic heart failure 
patients treated with enalapril in the SOLVD study were less likely to develop weight loss [213]. Reduced 
energy expenditure and weight increase are seen as an undesirable side-effect of beta-blockers in 
general. In CHF patients, similar post-hoc observations in large beta-blocker trials, have confirmed that 
antagonising high catecholamine levels increases body weight.  
 
7.2. Compounds with anabolic activity 
In patients with CHF, an overall depletion of circulating anabolic hormones (i.e.; circulating total 
testosterone and free testosterone, dehydroepiandrosterone sulfate, and IGF-1) is associated with poor 
outcome [214]. Male hypogonadism is also often found in patients with cancer cachexia. In CHF patients, 
replacement therapy with testosterone did not seem to impact muscle bulk, but elicited a significant 
improvement in functional status [215]. The positive effects of anabolic steroids, as well as testosterone 
administration, on protein synthesis, have to be weighted against possible hazards, such as hepatic 
toxicity, virilising effects, fluid retention and  - in the case of testosterone - the development of prostate 
complications and malignancy. Further development and testing of non-steroidal androgen receptor 
modulators (SARMs) might lead to useful alternatives [216], as indeed observed in the case of ostarine 
[217] and enobosarm [218].  
Several cachectic-prone diseases represent a state of GH resistance: high levels of GH and inappropriately 
low circulating and locally expressed IGF-1, which is considered the main GH mediator [219]. Whereas 
studies with GH have yielded disappointing results, a more comprehensive approach might be the direct 
administration of IGF-1. By inhibiting FoxO-1, leading to downregulation of the ubiquitin E3 ligases Murf-
1 and MAFbx, sketelal proteosomal protein degradation is reduced, whereas, mainly through the 
PI3K/Akt pathway, synthesis is stimulated [54,56]. Recent experimental evidence suggests that IGF-1 
supplementation might be a viable option to treat cancer cachexia [220].  
Beta-adrenergic agonists inhibit both Ca2+ dependent proteolysis, and the FoxO mediated transcription 
of E3 ubiquitin ligases. Despite their effective promotion of muscle hypertrophy, their side-effects, 
especially short (tachycardia) as well a long-term (cardiac hypertrophy) cardiovascular risks, preclude 
current application [221]. In animal models, the newer generation beta-agonist, formoterol, elicited an 
anabolic response in skeletal muscle at very low doses, and might therefore be pursued in future 
investigations [222]. 
 
7.3. Anti-inflammatory drugs 
Increased levels of pro-inflammatory cytokines, both in the circulation, as well as locally at the level of 
the skeletal muscle, have been attributed a key role in the pathophysiology of cachexia and muscle 
-antibodies opened a new avenue of possible 
applications. Although not specifically studied as anti-cachectic drugs, CHF trials with etancercept [223] 
and infliximab [224] were prematurely stopped because of futility and toxicity, respectively. 
Nevertheless, these drugs are now successfully used to achieve disease control in patients with 
rheumatoid arthritis and Crohn’s disease. In addition, their potential anti-cachectic effects are still 
actively explored in the setting of COPD and cancer. The use of interleukin-6 monoclonal antibodies is still 
in its early stages. Since a whole cascade of pro- and anti-inflammatory adaptations characterizes 
cachexia-associated wasting, the “single target approach” of specific cytokine antibodies has been 
scrutinized. A more general anti-inflammatory approach, as well as the use of so-called 
“immunomodulators” could be of interest. Cyclooxygenase-2 inhibitors may be beneficial in 
counteracting muscle wasting. In patients with cancer cachexia, celecoxib indeed led to a significant 
increase of lean body mass and muscle strength [225]. Thalidomide, pentoxyfilline and statins all exert 
anti-inflammatory effects, but have, until now, not been specifically investigated in cachectic patients. 
Despite their potent anti-inflammatory effects, the successful application of 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitors in cardiovascular disease was not confirmed in clinical CHF 
trials [226]. Interestingly, low cholesterol levels, often already found in cachectic patients, may offset the 
pleiotropic characteristics of statins. Indeed, several in vitro experiments [227] support the neutralising 
effects of lipopolysaccharide by cholesterol micelles. The latter may at least partially explain for the 
unexpectedly improved outcome in CHF patients with elevated plasmalipids [228].  
 
7.4. Modulating the energetic crisis of skeletal muscle  
Together with GH resistance and downregulation of IGF-1, insulin resistance contributes to the 
anabolic/catabolic imbalance [229]. The exact mechanisms underlying the initiation of insulin resistance 
and its relation to muscle wasting remain to be further explored. In CHF patients, increased plasma fatty 
acids, pro-inflammatory cytokines, as well as local muscle adiponectin resistance, may culminate into an 
insulin resistant state. The adipocyte-derived cytokine adiponectin exerts beneficial insulin-sensitising 
and anti-inflammatory effects in situations of insulin resistance, such as obesity and diabetes [230]. 
Paradoxically, increased adiponectin levels infer poor prognosis in several chronic conditions, such as in 
the setting of CHF [231] and renal failure [232]. In skeletal biopsies taken from CHF patients, adiponectin 
expression was significantly upregulated, whereas the reverse was seen for the skeletal muscle 
adiponectin receptor AdipoR1 [233]. Skeletal muscle metabolic deficiency in CHF was further 
-regulation of 
several target genes, involved in the metabolism of free fatty acids and glucose. Interestingly, these 
changes were reversible with the introduction of a 4 months exercise training protocol [234]. Targeting 
insulin resistance by using insulin sensitizer such as thiazolidinediones [235], as well as the application of 
olism [236]. 
 
7.5. Specific proteasome inhibitors 
Several compounds designed to act as proteasome inhibitors such as the peptidyl aldehydes 
carbobenzoxyl-Ile-Glu(O-t-butyl)-Ala-leucinal (PSI), N-acetyl-leucyl-leucyl-norleucinal (LLN) or CBZ-leucyl-
leucyl-leucinal (MG132) have helped immensely in understanding the biological role and importance of 
the ubiquitin-proteasome system during muscle wasting. These compounds reduce the accelerated 
proteolysis in atrophying muscle and preserve muscle fiber diameter [237-241]. Moreover, inhibition of 
-kB in its inactive state, 
thus preventing the upregulation of MuRF1 and MaFbx/atrogin- -1 
and IL-6 [239,240]. Other beneficial effects are restoration of Akt phosphorylation, decreased apoptosis, 
enhanced locomotive activity and shortening of the rehabilitation period [239,240]. Besides peptide 
aldehyde inhibitors, the N-protected dipeptide Pyz-Phe-boroLeu (also known as PS-341, bortezomib or 
Velcade) is frequently used to inhibit nonlysosomal protein breakdown. It is a potent proteasome 
inhibitor and approved by the American Food and Drug Administration for treatment of multiple 
myeloma. Even though bortezomib can prevent excessive protein degradation and muscle wasting in 
animal models [242,243], its use is not yet approved in patients for treatment of muscle atrophy. Indeed, 
clinical trials with bortezomib for the treatment of cancer cachexia have not shown univocal results [244]. 
In this light, it is noteworthy that only a partial reduction of denervation-induced atrophy was observed 
in rat soleus muscle after treatment with bortezomib [242]. This partial effect could be due to other 
proteolytic mechanisms that are not inhibited by bortezomib, such as lysosomal pathways, which are also 
involved in muscle wasting (vide supra). Peptide aldehyde inhibitors such as MG132 can repress certain 
lysosomal cysteine proteases and calpains, which might explain the total rescue of muscle mass in some 
studies [240]. 
 
7.6. Exercise training – an all-in-one approach? 
The multiple effects of exercise training in reversing atrophy and – especially – the hypertrophic stimulus 
of resistance exercises are well known. Regular physical activity, for instance, in patients with CHF, has 
local and general anti-inflammatory [245,246] and anti-oxidative effects [247], decreases insulin and 
adiponectin resistance [234], has a quiescent influence on the over-activated UPS [248] and reduces 
skeletal muscle apoptosis [247]. The resulting improvement in terms of physical capacity and quality of 
life in CHF and COPD patients has stimulated investigators to explore this treatment modality in other 
conditions, such as cancer, renal failure and rheumatoid arthritis. Very recent experimental data suggest 
that in pressure overload-induced heart failure [249], myostatin, produced in the heart itself, translates 
into remote effects of peripheral muscle wasting. These data are somewhat contradictory to findings 
form an earlier study, using a different heart failure model (LAD ligation), in which local skeletal muscle 
myostatin upregulation was shown [250]. Whereas targeted inhibition of myostatin, by using myostatin 
antibodies or activin receptor IIB blockers might be a future therapeutic option, it is interesting to 
mention that exercise training of animals following LAD ligation significantly downregulated skeletal 
muscle and myocardial myostatin protein overexpression [251]. In that same study, using a C2C12 cell 
-dependent pathway involving NF-  
Very recently, a combined approach of eicosapentaenoic acid (EPA) and exercise training has been tested 
on Lewis lung carcinoma-bearing mice [252]. While EPA alone did not prevent the muscle loss induced by 
tumor growth, the combination with exercise induced a partial rescue of muscle strength and mass in 
cachectic animals, as corroborated by reduced PAX-7 accumulation and increased PCG-1 protein [252]. 
 
8. Conclusions 
Muscle atrophy may arise as a consequence of many different physiological and pathological processes. 
Regardless of these underlying conditions, counteracting loss of muscle mass is a major issue that should 
be addressed in order to increase the quality of life in severely ill patients. Based on research conducted 
in different areas, it is strongly suggested that a plethora of combinations, comprising unbalanced 
triggers and activated or deactivated pathways, eventually culminate into a hypercatabolic status. These 
observations clearly lead up to the necessity of elaborating a multi-facetted therapeutic approach, that 
involves adequate nutritional support, the implementation of exercise training to stimulate muscle 
hypertrophy and, one or more pharmacological compounds that specifically antagonize pro-atrophic 
pathways. Because of the complexity of each disease and the variation of skeletal muscle wasting among 
patients, the clinical approach needs to be personalized in order to obtain a targeted therapy and to 
avoid dangerous side-effects.  
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Fig. 1: Pathophysiological events associated with muscle atrophy. 
 
Table 1: Overview of different therapeutic approaches employed to counteract muscle wasting. 
 
Therapeutic approach Class Molecule References 
Dietary supplementation 
 BCCAs Leu, Ile, Val, Hmb [206,207] 
 
 PUFAs EPA, DHA [208,209] 
 
 Appetite stimulants Anti-histaminic drugs,                                progestational agents,                        
ghrelin [210] 
 
 ACE inhibitors Enalapril [213] 
 
Compounds with anabolic activity Steroidal androgens Testosterone [215] 
 
 SARMs Ostarine  
and enobosarm  [216-218]  
 
 Growth factors IGF-1, insulin [220] 
 
 Beta2-agonist Formoterol [222] 
 
 
Anti-inflammatory drugs 
  Etancercept, infliximab  [223,224] 
 
 Cyclooxygenase-2 inhibitors  Celecoxib [225] 
 
 
Modulating the energetic crisis of skeletal muscle 
 adipocyte-derived cytokine Adiponectin (diabetes and obesity) [230] 
 
 Insulin sensitizer Thiazolidinediones [235] 
 
  Fibrates  [236] 
 
 
Muscle wasting inhibitors 
 Proteasome inhibitors PSI, LLN, MG132 [237-241] 
 
  PS-341, bortezomib or Velcade [242-244] 
 
Exercise training  PRT  PRT, endurance [234,245-247] 
 
 PRT combined with therapeutic strategies PRT and Eicosapentaenoic acid [252] 
 
 
 
Table abbreviations: ACE, angiotensin converting enzyme; BCCAs, branched chain aminoacids; Hmb, β-
hydroxy β-methylbutyrate; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; IGF-1, insulin-like 
-activated receptors alpha; PRT, regular physical training; 
PUFAs, polyunsaturated fatty acids; SARMs, non-
necrosis alpha. 
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